Clinical Trial Update: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 efficacy evaluation comparing BAT5906 to Lucentis in neovascular age-related macular degeneration has completed, with efficacy data reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• BAT5906 (BAT5906)
• Lucentis (ranibizumab)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Neovascular (Wet) Age-related Macular Degeneration | Phase 3 | Status: COMPLETED